Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"The new year holds a great deal of promise for the field of regenerative medicine, with companies like NEO at the forefront." (12/30/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak Moreá>
Companies Commented On
- Actinium Pharmaceuticals Inc.
- AstraZeneca Plc
- Bellicum Pharmaceuticals Inc.
- Bristol-Myers Squibb Co.
- Celator Pharmaceuticals
- Cellular Biomedicine Group Inc.
- Incyte Corp.
- Juno Therapeutics
- Kite Pharma
- Merck & Co. Inc.
- Merrimack Pharmaceuticals Inc.
- Novartis AG
- Pfizer Inc.
- Roche Holding AG
- StemCells Inc.
- Sunesis Pharmaceuticals Inc.
LifeTech Capital President and Senior Managing Director Stephen Dunn was previously the managing director of Life Sciences Research at Jesup & Lamont, as well as director of research for Dawson James Securities and director of Life Sciences at Cabot Adams venture capital group. He has held management positions in business development, finance and operations, having worked in more than 25 countries in North America, Europe and the Far East with biomedical companies including Beckman Coulter, Coulter, Cordis (Johnson & Johnson) and Telectronics (St. Jude Medical), as well as several smaller companies. With more than 25 years in the global biomedical industry, Dunn has negotiated numerous intellectual property licenses, product development agreements, venture funding, mergers and acquisitions and joint ventures. Dunn is a five-star biotechnology analyst on StarMine and has appeared in both the financial and scientific media, including The Wall Street Journal, CNN, Newsweek, Forbes, Nightly Business Report, Nature Biotechnology, The Scientist, BioWorld and many other media outlets. He is a frequent speaker and panel member for many financial, medical and venture capital events.
Immuno-Oncology Promises Continued Wealth and Health: LifeTech Capital's Stephen Dunn (2/19/15) Immuno-oncologyŚdisabling cancer's defenses so that a patient's own immune system can seek it out and destroy itŚtook center stage in the drug development world in 2014. Stephen Dunn of LifeTech Capital believes that preeminence will continue in 2015, bolstered by new drug approvals, new targets and new combination immunotherapies that increase potency. In this interview with The Life Sciences Report, Dunn outlines how companies large and small are leveraging these therapies, and where investors should look for opportunity in the sector.
ASCO Abuzz About Immunotherapies: A Preview of the Latest in Cancer Therapy from Stephen Dunn (5/28/14) Working in what is arguably the hottest sector in the drug development industry, biotech researchers continue to ferret out cancer's secrets. The premier event for those in the field is the American Society of Clinical Oncology annual meeting, taking place in Chicago from May 30 to June 1. Participants have submitted abstracts for promising therapies in advance of the conference, profiling new compounds that could lead to better outcomes for patients and bolster the health of investment portfolios. In this interview with The Life Sciences Report, LifeTech Capital's Stephen Dunn walks us through some of the highlights.
Can Stem Cells Regenerate Your Portfolio? Stephen Dunn Says Yes (9/27/12) Once the subject of intense political debate, stem cell therapies may soon be a therapeutic mainstay of healthcare. In this exclusive interview with The Life Sciences Report, LifeTech Capital's President and Senior Managing Director of Research Stephen Dunn explores the history of stem cell therapy and discusses companies that are reviving this "old" technique for profit.
"ATNM is developing Iomab-B for acute myeloid leukemia patients undergoing a bone marrow transplant." (5/28/14) Actinium Pharmaceuticals Inc. - The Life Sciences Report Interview with Stephen Dunn Moreá>
"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) Neuralstem Inc. - The Life Sciences Report Interview with Edward Stopke Moreá>
"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) Athersys Inc. - The Life Sciences Report Interview with Edward Stopke Moreá>
"The research synergy with Gilead and Merck could prove fruitful for RNN in terms of acquisition potential." (1/22/15) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Edward Stopke Moreá>